Znn3bq.jpeg
²é¿´: 1696  |  »Ø¸´: 10
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

PSA

ר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)

[½»Á÷] NDA for tasocitinib to treat RA ÒÑÓÐ5È˲ÎÓë

Pfizer Inc. (NYSEFE), New York, N.Y.
Product: Tofacitinib (CP-690,550) (formerly tasocitinib)
Business: Autoimmune
Molecular target: Janus kinase-3 (JAK-3); Janus kinase-1 (JAK-1)
Description: Oral pan-Janus kinase (JAK) inhibitor
An NDA for tofacitinib to treat rheumatoid arthritis (RA) is
under FDA review with an Aug. 21 PDUFA date, while an MAA is
under review in the EU. The product is also under review in Japan.
In a conference call to discuss its 2Q12 earnings, Pfizer said FDA
requested additional analysis of data in the NDA for tofacitinib,
which the pharma said could cause the agency to extend its review
of the product past its PDUFA date. Specifics about the request
were not disclosed (see BioCentury, Aug. 6). Tofacitinib also is in
Phase III testing to treat moderate to severe plaque psoriasis.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan) has
rights from Pfizer to co-market tofacitinib in Japan for RA and other
undisclosed indications
»Ø¸´´ËÂ¥

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

ÐÂÒ©·¢ÏÖ

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

z1278849487

гæ (³õÈëÎÄ̳)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÎÒÏë×ö¿ÆÑУ¬ÎÒÃÇÀÏʦ¸øÁËÎÒÕâÑùÒ»¸öÌâÄ¿£ºtofacitinibµÄMe TooÒ©µÄ¿ª·¢Ñо¿£¬Ëû˵tofacitinibÊÇ2012ÄêPfizerÉÏÊеÄÖØ°õÐÂÒ©£¬ÊÇJAK3ÒÖÖÆ¼Á£¬Ö÷ÖÎÀà·çʪÐԹؽÚÑ×£¬ÎÒÃÇ¿ÉÒÔ¶ÔËûµÄ·Ö×Ó½øÐÐÐÞÊΣ¬²¢ºÏ³ÉËûµÄÀàËÆÎÖ÷ҪʹÓÃһЩ´øÓÐÔÓÔ­×ӵĻ·Ìæ´úÏÖÓдóµÄßÁऻ·£¬ÓÃàÑßÊ¡¢ßÅßáµÈÌæ´úÆäÏÖÓеÄ6²¢5»·£¬µÃµ½µÄÀàËÆÎï½øÐÐÌåÍâ»îÐԲⶨ¡£

µ«ÎÒÒ»µã˼·ҲûÓУ¬´ó¼ÒÄܸøÎÒһЩ½¨Ò飬лл¡£
9Â¥2013-02-20 00:04:19
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 11 ¸ö»Ø´ð

cpujacs

ÈÙÓþ°æÖ÷ (ÖªÃû×÷¼Ò)

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷


¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan) has rights from Pfizer to co-market tofacitinib in Japan for RA and other undisclosed indications
ÕâÖÖºÏ×÷ÊDz»Êǽ«À´µÄÒ»ÖÖÇ÷ÊÆ
3Â¥2012-08-20 13:15:10
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

PSA

ר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)

ºÏ×÷¿ª·¢£¬Í¦ºÃµÄºÇºÇ£¡
4Â¥2012-08-20 13:22:26
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

PSA

ר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)

ÒýÓûØÌû:
5Â¥: Originally posted by Ò©µÀÈË at 2012-08-20 14:29:39
²»¿´ºÃ

Äã²»¿´ºÃtofacitinibÉÏÊУ¿»¹ÊDz»¿´ºÃºÏ×÷¿ª·¢ºÇºÇ£¡
6Â¥2012-08-20 15:29:08
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 283Çóµ÷¼Á£¬¹¤¿Æ£¡ +8 ËÕ´òË®7777 2026-04-08 8/400 2026-04-09 20:50 by xujun0624
[¿¼ÑÐ] 289Çóµ÷¼Á +4 L1ttleTiger 2026-04-04 4/200 2026-04-09 19:53 by xiayizhi
[¿¼ÑÐ] 314Çóµ÷¼Á +16 xhhdjdjsjks 2026-04-09 17/850 2026-04-09 18:26 by ºÈ×í¾ÆN
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á325·Ö +13 15771691647 2026-04-04 15/750 2026-04-09 16:55 by 15771691647
[¿¼ÑÐ] 085600²ÄÁÏÓ뻯¹¤×¨Ë¶329 Çóµ÷¼Á +24 ¶îcc 2026-04-06 25/1250 2026-04-09 16:01 by wp06
[¿¼ÑÐ] 0860004 Çóµ÷¼Á 309·Ö +6 Yin DY 2026-04-09 6/300 2026-04-09 10:19 by °¡Àî999
[¿¼ÑÐ] 086000µ÷¼Á +4 Ê®Æßsa 2026-04-07 4/200 2026-04-09 09:27 by Ò¼ÍùŸoǰ
[¿¼ÑÐ] Ò»Ö¾Ô¸»ª¶«Àí¹¤085601²ÄÁϹ¤³Ì303·ÖÇóµ÷¼Á +15 a1708 2026-04-06 15/750 2026-04-08 16:23 by luoyongfeng
[¿¼ÑÐ] Ò»Ö¾Ô¸211£¬»¯Ñ§Ñ§Ë¶£¬310·Ö£¬±¾¿ÆÖصãË«·Ç£¬Çóµ÷¼Á +10 ŬÁ¦·Ü¶·112 2026-04-07 10/500 2026-04-08 15:01 by screening
[¿¼ÑÐ] 274Çóµ÷¼ÁÇóµ÷¼Á +10 Jachenbingoo 2026-04-06 13/650 2026-04-08 14:25 by zhq0425
[¿¼ÑÐ] µ÷¼Á +3 µçÆø300Çóµ÷¼Á²» 2026-04-08 6/300 2026-04-08 09:39 by µçÆø300Çóµ÷¼Á²»
[¿¼ÑÐ] ²ÄÁÏÇóµ÷¼Á +18 Ò»ÑùYWY 2026-04-05 18/900 2026-04-07 15:49 by dxlg
[¿¼ÑÐ] 26×ÔÈ»µØÀíѧ303·ÖÇóµ÷¼Á +4 Ò»Õ½³É˶°¡°¡°¡° 2026-04-06 9/450 2026-04-06 20:35 by lin-da
[¿¼ÑÐ] Çóµ÷¼Á +5 wos666 2026-04-03 5/250 2026-04-06 10:13 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 331Çóµ÷¼Á +8 ÓÚÕ÷yz 2026-04-05 8/400 2026-04-06 00:54 by fmesaito
[¿¼ÑÐ] 308Çóµ÷¼Á +3 ÖÕ²»ËÆ´Óǰ 2026-04-05 3/150 2026-04-05 20:07 by à£à£à£0119
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +9 ¸ï΢¹ð 2026-04-04 9/450 2026-04-05 08:27 by 544594351
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +12 Ò»ÑùYWY 2026-04-04 12/600 2026-04-05 08:24 by 544594351
[¿¼ÑÐ] 283Çóµ÷¼Á +4 mcbbc 2026-04-03 5/250 2026-04-04 20:51 by imissbao
[¿¼ÑÐ] µ÷¼Á0855-288 +5 xÐܶþa 2026-04-03 5/250 2026-04-04 00:19 by Öí»á·É
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û